Abstract | OBJECTIVE: MATERIALS AND METHODS: This is a retrospective, longitudinal study of 23 patients with ATTR-CA (10 ATTRm and 13 ATTRwt) diagnosed at the Cleveland Clinic from May 2007 to August 2017 who were treated with diflunisal. Patients were prescribed diflunisal, fully informed of the risks of side effects. Patient characteristics and subsequent adverse events were recorded. RESULTS: CONCLUSION:
Diflunisal was well-tolerated in both the ATTRm- and ATTRwt-CA populations. Withdrawal due to side effects was related to gastrointestinal complaints, but most patients had no adverse events. Diflunisal can be safely used in a selected group of ATTR-CA patients with appropriate clinical, renal and hematologic monitoring.
|
Authors | Asad Ikram, Joseph P Donnelly, Brett W Sperry, Christy Samaras, Jason Valent, Mazen Hanna |
Journal | Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
(Amyloid)
Vol. 25
Issue 3
Pg. 197-202
(Sep 2018)
ISSN: 1744-2818 [Electronic] England |
PMID | 30388377
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Prealbumin
- Diflunisal
|
Topics |
- Aged
- Amyloidosis
(drug therapy, genetics)
- Anti-Inflammatory Agents, Non-Steroidal
- Cardiomyopathies
(drug therapy, genetics)
- Diflunisal
(therapeutic use)
- Female
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Prealbumin
(genetics)
- Retrospective Studies
|